NEW YORK, March 5 - Ciphergen Biosystems and Beckman Coulter on Tuesday said they plan to automate clinical proteomics research.
Terms of the agreement call for Ciphergen to combine its SELDI protein chip biomarker system with a custom version of Beckman's Biomek 2000 system. The resulting "turnkey" platform will be marketed to industry, academia, and government institutes, the companies said.
Financial terms of the agreement were not disclosed.
"We are happy that we can now make these solutions available broadly through this alliance with Beckman Coulter," William E. Rich, president and CEO of Ciphergen, said in a statement. The firms said their alliance hopes to speed sample throughput five-fold and improve reproducibility.